Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ: JANX )

30.22 -0.42 (-1.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Janux Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate at Upcoming May 2023 Investor Conferences
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX008 in First-in-Human Phase 1 Clinical Trial in Patients with Solid Tumors
From Janux Therapeutics
Via Business Wire
Janux Therapeutics's Return On Capital Employed Overview
Via Benzinga
Why Janux Therapeutics Shares Rose 33.1% This Week
The clinical-stage biotech company just began its first clinical trial. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2023
Via Benzinga
7 Biotech Stocks That Could Be the Next Big Thing
Although speculation might be a tough call at this juncture, these biotech stocks and their underlying science might be compelling enough. 
Via InvestorPlace
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Janux Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Janux Therapeutics to Participate in Novel IO Panel Discussion at Cowen's 43rd Annual Health Care Conference
From Janux Therapeutics, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Versus Systems Inc. (NASDAQ: VS) surged 270% to $2.26 after the company announced it will partner with Resolve to bring generative AI and gamification to customer payments and credit... 
Via Benzinga
Janux Therapeutics Announces Submission of Investigational New Drug Application for JANX008, an EGFR-TRACTr for Solid Tumors
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics to Present at Upcoming Investor Conferences in November
From Janux Therapeutics, Inc.
Via Business Wire
7 Short-Squeeze Stocks for Bold Contrarians to Consider
While market volatility has brough the bears out of hibernation, certain short-squeeze stocks could be a trap for the pessimists. 
Via InvestorPlace
Janux Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Janux Therapeutics Announces First Patient Dosed with JANX007 in First-in-Human Phase 1 Clinical Trial in Patients with Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
7 Short-Squeeze Stocks to Buy for Contrarian Investors
The pessimists may have bitten off more than they can chew for these intriguing contrarian market ideas. 
Via InvestorPlace
Janux Therapeutics Appoints Brenda Van Vreeswyk as Head of Human Resources
From Janux Therapeutics, Inc.
Via Business Wire
Why NLS Pharmaceutics Shares Tumbled Over 66%; Here Are 68 Biggest Movers From Yesterday
Gainers PepGen Inc. (NASDAQ: PEPG) jumped 110.2% to close at $10.93 after the company announced results from its Phase 1 healthy volunteer trial of PGN-EDO51 for Duchenne Muscular Dystrophy. The trial... 
Via Benzinga
Janux Therapeutics Appoints Winston Kung to Board of Directors
From Janux Therapeutics, Inc.
Via Business Wire
Why Prothena Corporation Shares Are Trading Higher By 76%, Here Are 53 Stocks Moving In Wednesday's Mid-Day Session
Gainers 
Via Benzinga
Janux Therapeutics to Participate and Present at Upcoming Investor Conferences in September
From Janux Therapeutics, Inc.
Via Business Wire
Why Minerva Neurosciences Shares Traded Higher By Over 66%; Here Are 78 Biggest Movers From Yesterday
Gainers Minerva Neurosciences, Inc. (NASDAQ: NERV) shares gained 66.5% to close at $7.51 after Point72 Asset Management reported an 8.8% passive stake in the company. 
Via Benzinga
Advance Auto Parts, Nordstrom And Other Big Stocks Recording Losses On Wednesday
U.S. stocks closed higher with the Nasdaq Composite gaining 50 points on Wednesday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Janux Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
From Janux Therapeutics, Inc.
Via Business Wire
Zendesk, Quotient, + 40 Stocks Moving In Friday's Mid-Day Session
Gainers USA Truck, Inc. (NASDAQ: USAK) shares jumped 111% to $30.76. DB Schenker and USA Truck announced plans to combine and create premier North American transportation solutions provider. 
Via Benzinga
Looking Into Janux Therapeutics's Return On Capital Employed
According to Benzinga Pro data, during Q1, Janux Therapeutics (NASDAQ:JANX) posted sales of $1.59 million. Earnings were up 0.04%, but Janux Therapeutics still reported an overall loss of $13.41... 
Via Benzinga
Janux Therapeutics to Present at 2022 Jefferies Global Healthcare Conference
From Janux Therapeutics
Via Business Wire
Janux Therapeutics Announces FDA Clearance of Investigational New Drug Application for JANX007, a PSMA-TRACTr for Metastatic Castration-Resistant Prostate Cancer
From Janux Therapeutics, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.